Table 2.
Association between new use of benzodiazepine with incident dementia in PAQUID study. Values are numbers (percentages) unless stated otherwise
| Incident dementia | No dementia during follow-up | Hazard ratio (95%CI) | |
|---|---|---|---|
| Analysis adjusted for age* | (n=253) | (n=810) | |
| Benzodiazepine non-users | 223 (88) | 745 (92.0) | 1.00 |
| Benzodiazepine new users | 30 (12) | 65 (8.0) | 1.59 (1.09 to 2.34) |
| Main analysis† | (n=240) | (n=766) | |
| Benzodiazepine non-users | 211 (88) | 708 (92.4) | 1.00 |
| Benzodiazepine new users | 29 (12) | 58 (7.6) | 1.60 (1.08 to 2.38) |
| Complementary analysis†‡ | (n=231) | (n=752) | |
| Benzodiazepine non-users | 203 (88) | 695 (92.4) | 1.00 |
| Benzodiazepine new users | 28 (12) | 57 (7.6) | 1.62 (1.08 to 2.43) |
*At baseline (T5).
†Adjusted for age, sex, schooling duration, singleness, wine consumption, use of antihypertensive drugs, use of antidiabetic agents, use of statins, use of platelet inhibitors or oral anticoagulants, and mini-mental state examination evolution between inclusion (T0) and three year follow-up visit (T3).
‡Adjusted for significant depressive symptoms according Center for Epidemiologic Studies depression scale (score ≥17 for men; ≥23 for women) at baseline (T5).